In the last trading session, 1.35 million Milestone Pharmaceuticals Inc (NASDAQ:MIST) shares changed hands as the company’s beta touched 1.81. With the company’s per share price at $1.99 changed hands at $0.03 or 1.53% during last session, the market valuation stood at $106.12M. MIST’s last price was a discount, traded about -38.19% off its 52-week high of $2.75. The share price had its 52-week low at $1.12, which suggests the last value was 43.72% up since then. When we look at Milestone Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.79 million shares, with the 3-month average coming to 584.30K.
Analysts gave the Milestone Pharmaceuticals Inc (MIST) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.40. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MIST as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Milestone Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.15.
Milestone Pharmaceuticals Inc (NASDAQ:MIST) trade information
Instantly MIST was in green as seen at the end of in last trading. With action 0.51%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -15.68%, with the 5-day performance at 0.51% in the green. However, in the 30-day time frame, Milestone Pharmaceuticals Inc (NASDAQ:MIST) is -8.29% down. Looking at the short shares, we see there were 0.45 million shares sold at short interest cover period of 2.46 days.
The consensus price target for the stock as assigned by Wall Street analysts is 10, meaning bulls need an upside of 80.1% from its current market value. According to analyst projections, MIST’s forecast low is 10 with 10 as the target high. To hit the forecast high, the stock’s price needs a -402.51% plunge from its current level, while the stock would need to soar -402.51% for it to hit the projected low.
Milestone Pharmaceuticals Inc (MIST) estimates and forecasts
Data shows that the Milestone Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 48.51% over the past 6 months, a 55.40% in annual growth rate that is considerably higher than the industry average of 15.90%. Year-over-year growth is forecast to reach -100.00% down from the last financial year.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -7.22%. The 2025 estimates are for Milestone Pharmaceuticals Inc earnings to increase by 54.82%, but the outlook for the next 5-year period is at 26.29% per year.
MIST Dividends
Milestone Pharmaceuticals Inc is expected to release its next quarterly earnings report in March.
Milestone Pharmaceuticals Inc (NASDAQ:MIST)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.69% of Milestone Pharmaceuticals Inc shares while 57.01% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 57.41%. There are 57.01% institutions holding the Milestone Pharmaceuticals Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 9.9119% of the shares, roughly 4.97 million MIST shares worth $6.56 million.
RTW INVESTMENTS, LP holds the second largest percentage of outstanding shares, with 6.4921% or 3.26 million shares worth $4.3 million as of 2024-06-30.
